Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/2C-X/Safety & Risk Management

2C-X for Safety & Risk Management

1 paper and 0 clinical trials exploring 2c-x as a treatment for safety & risk management.

CompoundPhenethylamine

2C-X

2C-X denotes a family of synthetic phenethylamine psychedelics defined by a 2,5-dimethoxyphenethylamine scaffold. 2C-B is the best-studied member, with emerging controlled human data benchmarking it against psilocybin and MDMA.

Full 2C-X profile
IndicationMental health disorders affect over 900 million people worldwide, with conditions like PTSD and depression being among the most prevalent.

Safety & Risk Management

Safety and risk management in psychedelic therapy remains a critical area of research, necessitating vigilant assessment of potential adverse effects as clinical usage expands. Current efforts focus on ensuring that therapeutic practices minimise harm while maximising efficacy for a range of conditions.

Full Safety & Risk Management profile

Academic Research

1 paper
Paywallmeta

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

This academic book chapter (2017) reviews the pharmacology and toxicology of N-benzylphenethylamine (NBOMe) hallucinogens (including 2C-B). It found that rhabdomyolysis is a fairly common complication of severe NBOMe toxicity, which can be linked to NBOMe-induced hyperthermia, seizures, and vasoconstriction.

Published
January 18, 2017
Journal
Current Topics in Behavioral Neurosciences
Authors
Halberstadt, A. L.

Clinical Trials

0 trials

No clinical trials have been tagged with both 2C-X and Safety & Risk Management yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 2C-X papers Search all Safety & Risk Management trials Full 2C-X profile Full Safety & Risk Management profile